Safety Study of a Genetically Modified Adenovirus in Ovarian Cancer Patients
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to determine the maximally tolerated dose and spectrum
of toxicities encountered with intraperitoneal delivery of a RGD modified conditionally
replicative adenovirus (Ad5-Delta 24RGD) in patients with recurrent ovarian cancer.
Secondary objectives :
- To determine the biologic effects encountered with intraperitoneal delivery of Ad5-Delta
24RGD in patients with recurrent ovarian cancer cells
- To determine immunologic response generated against Ad5-Delta 24RGD when administered
intraperitoneally to patients with recurrent ovarian adenocarcinoma
- To determine potential clinical activity of Ad5-Delta 24RGD when administered
intraperitoneally to patients with recurrent ovarian adenocarcinoma